Show simple item record

dc.contributor.authorSharma, Rajesh
dc.contributor.authorAbbasi-Kangevari, Mohsen
dc.contributor.authorKisa, Adnan
dc.contributor.authorVos, Theo
dc.contributor.authorNaghavi, Mohsen
dc.contributor.authorKisa, Sezer
dc.contributor.authorColorectal Cancer Collaborator, GBD 2019
dc.date.accessioned2022-08-22T09:24:25Z
dc.date.available2022-08-22T09:24:25Z
dc.date.created2022-04-10T18:06:34Z
dc.date.issued2022-06-13
dc.identifier.citationThe Lancet Gastroenterology and Hepatology. 2022, .en_US
dc.identifier.issn2468-1253
dc.identifier.urihttps://hdl.handle.net/11250/3012865
dc.description.abstractBackground: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidence, mortality, and disability-adjusted life years (DALYs) for colorectal cancer were generated as a part of the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019 by age, sex, and geographical location for the period 1990–2019. Mortality estimates were produced using the cause of death ensemble model. We also calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. Findings: Globally, between 1990 and 2019, colorectal cancer incident cases more than doubled, from 842 098 (95% uncertainty interval [UI] 810 408–868574) to 2·17 million (2·00–2·34), and deaths increased from 518 126 (493 682–537 877) to 1·09 million (1·02–1·15). The global age-standardised incidence rate increased from 22·2 (95% UI 21·3–23·0) per 100000 to 26·7 (24·6–28·9) per 100000, whereas the age-standardised mortality rate decreased from 14·3 (13·5–14·9) per 100 000 to 13·7 (12·6–14·5) per 100 000 and the age-standardised DALY rate decreased from 308·5 (294·7–320·7) per 100000 to 295·5 (275·2–313·0) per 100000 from 1990 through 2019. Taiwan (province of China; 62·0 [48·9–80·0] per 100000), Monaco (60·7 [48·5–73·6] per 100000), and Andorra (56·6 [42·8–71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0–37·1] per 100 000), Brunei (30·3 [26·6–34·1] per 100 000), and Hungary (28·6 [23·6–34·0] per 100000) had the highest age-standardised mortality rates. From 1990 through 2019, a substantial rise in incidence rates was observed in younger adults (age <50 years), particularly in high Socio-demographic Index (SDI) countries. Globally, a diet low in milk (15·6%), smoking (13·3%), a diet low in calcium (12·9%), and alcohol use (9·9%) were the main contributors to colorectal cancer DALYs in 2019. Interpretation: The increase in incidence rates in people younger than 50 years requires vigilance from researchers, clinicians, and policy makers and a possible reconsideration of screening guidelines. The fast-rising burden in low SDI and middle SDI countries in Asia and Africa calls for colorectal cancer prevention approaches, greater awareness, and cost-effective screening and therapeutic options in these regions.en_US
dc.description.sponsorshipFunding provided by the Bill & Melinda Gates Foundation.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesThe Lancet Gastroenterology and Hepatology;Volume 7, Issue 7
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectColorectal canceren_US
dc.subjectCancer incidence ratesen_US
dc.subjectCancer screeningen_US
dc.subjectCancer burdenen_US
dc.subjectCancer treatment strategiesen_US
dc.subjectGlobal studiesen_US
dc.titleGlobal, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doihttps://doi.org/10.1016/S2468-1253(22)00044-9
dc.identifier.cristin2016544
dc.source.journalThe Lancet Gastroenterology and Hepatologyen_US
dc.source.volume7en_US
dc.source.issue7en_US
dc.source.pagenumber627-647en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal